Hematology (non-malignant) drugs

52 results

  • adakveo

    (crizanlizumab)
    Novartis Pharmaceuticals Corporation
    ADAKVEO® is indicated for reducing the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 and older with sickle cell disease.

  • afstyla

    (ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT)
    CSL Behring Lengnau AG
    AFSTYLA is indicated for adults and children with hemophilia A to control bleeding episodes, provide routine prophylaxis to reduce bleeding frequency, and manage perioperative bleeding. It is not indicated for von Willebrand disease treatment.

  • alprolix

    (Coagulation Factor IX (Recombinant), Fc Fusion Protein)
    Bioverativ Therapeutics Inc.
    ALPROLIX is indicated for the on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis in adults and children with hemophilia B. It is not intended for inducing immune tolerance.

  • altuviiio

    (Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl)
    Bioverativ Therapeutics Inc.
    ALTUVIIIO is indicated for adults and children with hemophilia A for routine prophylaxis to reduce bleeding episodes, on-demand treatment, and perioperative bleeding management. It is not intended for treating von Willebrand disease.

  • alvaiz

    (Eltrombopag)
    Teva Pharmaceuticals, Inc.
    ALVAIZ (eltrombopag) is indicated for treating thrombocytopenia in patients with persistent or chronic immune thrombocytopenia, chronic hepatitis C, and severe aplastic anemia who have not responded adequately to other therapies. It is not approved for myelodysplastic syndromes or with direct-acting antiviral agents for hepatitis C.

  • auryxia

    (ferric citrate)
    Akebia Therapeutics, Inc.
    Auryxia is indicated for controlling serum phosphorus levels in adults with chronic kidney disease on dialysis and for treating iron deficiency anemia in adults with chronic kidney disease who are not on dialysis.

  • besremi

    (ropeginterferon alfa-2b)
    Pharmaessentia Usa Corporation
    BESREMi is indicated for the treatment of adults with polycythemia vera.

  • cablivi

    (caplacizumab)
    Genzyme Corporation
    CABLIVI is indicated for treating adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), used alongside plasma exchange and immunosuppressive therapy.

  • cerezyme

    (IMIGLUCERASE)
    Genzyme Corporation
    Cerezyme is indicated for the treatment of adults and pediatric patients aged 2 and older with Type 1 Gaucher disease associated with anemia, thrombocytopenia, bone disease, hepatomegaly, or splenomegaly.

  • doptelet

    (avatrombopag maleate)
    AkaRx, Inc.
    DOPTELET is indicated for treating thrombocytopenia in adult patients with chronic liver disease undergoing procedures and in those with chronic immune thrombocytopenia who have not responded adequately to prior treatments.